^
Association details:
| Biomarker: | PIK3CA amplification + PIK3CA mutation + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
Published date:
02/18/2022
Excerpt:
Clinical benefit (CB) in alpelisib-treated patients from two studies including 46 patients was analyzed. About 8-10% of HR + /HER2- primary BC had PIK3CA-mut/gain. In two of the datasets analyzed, among patients with PIK3CA mutant tumors, those with mut/gain had significantly worse outcome compared to those with CN neutral (PIK3CA-mut/neut) and PIK3CA-mut/gain remained an independent prognostic factor.
DOI:
10.1038/s41523-022-00382-5
